Heparina Sódica Sala (Heparin Sodium)

Heparina Sódica Sala is employed in several medical situations where anticoagulation is required. It is commonly selected for its rapid onset and reversible action.

• Anticoagulation during haemodialysis procedures to prevent circuit clotting.
• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Intra‑arterial anticoagulation during interventional cardiology or radiology procedures.
• Intravenous anticoagulation in surgical or critical‑care settings to reduce thrombotic risk.
• Management of acute coronary syndromes when rapid anticoagulation is indicated.

Heparina Sódica Sala may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common

• Minor bleeding at injection or catheter sites.
• Bruising or hematoma formation.
• Mild thrombocytopenia (platelet count reduction).
• Elevated liver enzymes.
• Local irritation or erythema.

Serious

• Major hemorrhage, including intracranial or gastrointestinal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Spontaneous spinal or epidural hematoma.
• Severe hypotension due to systemic bleeding.

Before using Heparina Sódica Sala, clinicians should assess patient‑specific risk factors and monitor relevant laboratory parameters.

• Verify baseline coagulation tests (aPTT, PT/INR) and platelet count.
• Adjust dose in patients with renal or hepatic impairment.
• Use cautiously in individuals with a history of bleeding disorders or recent surgery.
• Avoid use in patients with known hypersensitivity to heparin or pork products.
• Monitor for signs of heparin‑induced thrombocytopenia during therapy.
• Counsel pregnant or lactating patients only after risk‑benefit evaluation.

Heparina Sódica Sala can interact with several medications, affecting bleeding risk or anticoagulant efficacy.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or antiplatelet agents that increase bleeding.
• High‑dose aspirin or clopidogrel in patients at high hemorrhagic risk.

Use with caution

• Thrombolytic agents (e.g., alteplase) during acute clot dissolution.
• Certain antibiotics (e.g., vancomycin) that may potentiate anticoagulant effect.
• Hormonal therapies (e.g., estrogen) that affect coagulation balance.
• Herbal supplements such as ginkgo biloba or garlic that may increase bleeding tendency.